|Bid||27.75 x 100|
|Ask||36.45 x 100|
|Day's Range||32.80 - 33.46|
|52 Week Range||15.15 - 37.30|
|PE Ratio (TTM)||21.98|
|Earnings Date||Feb 5, 2018 - Feb 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.07|
LONDON, UK / ACCESSWIRE / December 14, 2017 / Active-Investors issued a free report on Myriad Genetics, Inc. (NASDAQ: MYGN ) ("Myriad"), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=MYGN ...
Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.
Myriad Genetics (MYGN) has predicted Vectra DA’s annual revenues to reach $100 million in the case of updated ACR guidelines and full reimbursement.
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) Vectra DA test reported revenues close to $16 million.
Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.
Cooper Companies (COO) continues to witness impressive results at the CooperVision business segment that delivered strong sales in Q4.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Myriad Genetics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
SALT LAKE CITY, Dec. 08, 2017-- Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict ® are being featured at ...
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
In fiscal 2018, Myriad Genetics (MYGN) expects to witness rapid expansion in reimbursement for GeneSight based on positive results of the 1,200-patient pharmacogenomic study.
Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.
Chemed (CHE) continues to display robust performance in Roto-Rooter business on strength in core plumbing and drain cleaning service segments.